PubMed Health⌕ Search

Biomedical subjects

Hao Meng

Publications and source records attributed to Hao Meng.

2 recordsLinked to original sources

BriGHT: transcriptome-regularized multimodal neuroimaging for brain disorder prediction.

MOTIVATION: Hypergraph-based models for brain disorder prediction mainly adopt imaging-derived hypergraphs as propagation backbones. However, the entanglement of topology construction and feature propagation leaves regional representations weakly constrained by underlying biological organization, making them vulnerable to subject-specific variation and noise, particularly in heterogeneous multimodal settings. RESULTS: We present BriGHT, a Brain transcriptome-reGularized Hypergraph framework for mulTimodal disorder prediction. BriGHT employs a transcriptome-derived structural reference as a soft anchoring prior to regularize neuroimaging ROI embeddings, stabilizing representation geometry while preserving disease-relevant subject-specific variation. BriGHT further incorporates a reliability-aware fusion module to estimate subject-specific modality reliability from prediction confidence, cross-modal consistency, and decision certainty, enabling adaptive integration under heterogeneous modality quality. Experiments on three neuroimaging cohorts (ADNI, ADHD-200, REST-meta-MDD) and four modalities (VBM, fMRI, FDG, AV45) demonstrate that BriGHT consistently outperforms competing graph/hypergraph learning methods across six brain disorder prediction tasks. Perturbation analyses show that BriGHT benefits from the spatial correspondence between transcriptomic modules and imaging ROIs, rather than from arbitrary hypergraph regularization alone. Ablation and meta-analytic interpretability analyses support the contribution of transcriptomic anchoring and adaptive fusion to robust and biologically meaningful brain disorder prediction. AVAILABILITY: The software is publicly available at: https://github.com/Yaolab-fantastic/BriGHT. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Journal Article↗

[Anterior chamber phakic intraocular lens implantation in highly myopic eyes].

OBJECTIVE: To investigate the stability, predictability and safety of angle-supported phakic intraocular lens (IOL) implantation in high myopia. METHODS: Seventy-six myopic eyes of 40 patients treated with anterior chamber angle-supported phakic IOL (Phakic6H) implantation were followed. The average myopia diopter was (-15.89 +/- 3.78) D (-9.50 to -26.25 D) and the best corrected visual acuity (BCVA) was (0.82 +/- 0.20) (0.5 to 1.0). The average follow-up time was 12 months. All the treated eyes were observed for anterior segment changes, uncorrected visual acuity (UCVA), BCVA, refraction, intraocular pressure (IOP) and corneal endothelium preoperatively and postoperatively. All data were analyzed in statistics. RESULTS: One year after the surgery, the average UCVA was (1.00 +/- 0.35) (0.3 to 1.5) and BCVA was (1.18 +/- 0.29) (0.5 to 1.5). The average residual refraction was (-0.40 +/- 0.64) D (-2.00 to +0.50 D). In 96.1% of eyes, the average residual refraction was within +/- 1.0 diopter. The average corneal endothelial count before and one year after the surgery was (3174 +/- 248)/mm(2) and (3067 +/- 320)/mm(2) (P < 0.01) respectively. The intraocular pressure before and one year after the surgery was (16.12 +/- 2.32) mmHg and (15.29 +/- 3.38) mmHg (P < 0.05) respectively. Two patients (4 eyes) complained of halo and glare. One patient's (2 eyes) pupils were oval and another one (2 eyes) showed decentered phakic IOL. Macular hemorrhage occurred in one patient (2 eyes) after eight months of surgery. CONCLUSIONS: Angle-supported phakic IOL implantation is effective for treatment of high myopia and the results are predictable. It deserves further clinical investigation. The effectiveness and safety of this kind of phakic IOL should be further observed for a long period of time.

Adult↗